Heated chemo drug tested for abdominal cancer spread
NCT ID NCT04761185
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety and tolerability of a chemotherapy drug called raltitrexed when given as a heated solution directly into the abdomen (HIPEC) in 30 patients with colorectal cancer. The goal was to find the highest safe dose and understand how the drug behaves in the body. The study is complete and will guide future research on this treatment approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Raltitrexed (a chemotherapy drug given as heated intraperitoneal chemotherapy)
- What this could lead to
- If successful, this could help determine a safe dose of raltitrexed for use in heated chemotherapy to control colorectal cancer spread in the abdomen.
- What could go wrong
- This is a very early (Phase 1) trial with only 30 participants, so results may not apply to all patients. The main goal is safety, not effectiveness, and there are risks of side effects from the chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?